ReviewJournal of central nervous system disease2022

Natalizumab extended-interval dosing in multiple sclerosis to mitigate progressive multifocal leukoencephalopathy risk: initial study evidence and real-world experience.

Julian Perncezky et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.